Zenas BioPharma, a clinical-stage biopharmaceutical company, has recently released its 10-K report, revealing a focus on the development and commercialization of transformative immunology-based therapies. The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to target various autoimmune diseases, with promising results reported in trials for IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus. Additionally, the company is developing other product candidates, such as orelabrutinib, ZB002, ZB004, and ZB001, to address a range of immunology and inflammation (I&I) indications.
In January 2026, Zenas BioPharma reported positive results from the Phase 3 trial of obexelimab in patients with IgG4-related disease, demonstrating a significant reduction in the risk of flare compared to placebo. The company plans to submit the Biologics License Application (BLA) to the FDA for the treatment of IgG4-related disease in the second quarter of 2026. Moreover, promising topline data was reported from the MoonStone trial for multiple sclerosis, with a statistically significant reduction in active inflammation markers. The company also entered into various license agreements, including with InnoCare Pharma Inc., to develop and commercialize orelabrutinib for multiple sclerosis worldwide.
Financially, Zenas BioPharma completed its initial public offering (IPO) in September 2024, generating net proceeds of $234.3 million. In October 2025, the company closed a private investment in public equity (PIPE) offering, issuing 6,311,030 shares of common stock for net proceeds of $111.8 million. Additionally, the company entered into a loan agreement in March 2026, providing for up to a $250.0 million term loan facility. However, the company has incurred significant operating losses, with net losses of $377.7 million in 2025 and an accumulated deficit of $765.1 million as of December 31, 2025. Zenas BioPharma expects to continue incurring significant losses as it advances its product candidates through clinical development and seeks regulatory approvals.
As a result of these announcements, the company's shares have moved 1.15% on the market, and are now trading at a price of $20.16. For the full picture, make sure to review Zenas BioPharma's 10-K report.
